Skip to main content
placeholder image

Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Journal Article


Abstract


Publication Date


  • 2010

Citation


  • Felip, E., Ranson, M., Cedres, S., Brewster, M., Mcnally, V., Venturi, M., . . . Galdermans, D. (2010). Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 28(15_suppl), 7540. doi:10.1200/jco.2010.28.15_suppl.7540

Web Of Science Accession Number


Start Page


  • 7540

End Page


  • 7540

Volume


  • 28

Issue


  • 15_suppl

Abstract


Publication Date


  • 2010

Citation


  • Felip, E., Ranson, M., Cedres, S., Brewster, M., Mcnally, V., Venturi, M., . . . Galdermans, D. (2010). Biomarker analyses from a phase l study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 28(15_suppl), 7540. doi:10.1200/jco.2010.28.15_suppl.7540

Web Of Science Accession Number


Start Page


  • 7540

End Page


  • 7540

Volume


  • 28

Issue


  • 15_suppl